B. bifidum

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Overall, research on Bifidobacterium bifidum (B. bifidum) is most developed in three intersecting areas: (1) life-course microbiome ecology (especially infancy and early childhood), (2) mechanistic studies of host–microbe interactions in the gut (mucus utilization, epithelial barrier function, immune signaling), and (3) preclinical disease models where B. bifidum is tested as a probiotic intervention (e.g., colitis and cancer-related outcomes). Multiple reviews and population studies emphasize that bifidobacteria are prominent in breast-fed infants and shift in composition with age; within this broader genus-level literature, B. bifidum is repeatedly detected across ages and is often discussed alongside other infant-associated species (e.g., B. longum, B. breve). Mechanistic work highlighted in these abstracts focuses on strain-specific traits—such as mucin-associated carbohydrate degradation, sialidase activity, mucus penetration, and adhesion—that plausibly support colonization and functional effects in the intestinal niche.

The strongest evidence in the provided abstracts supports two conclusions. First, B. bifidum can exert strain-dependent effects on intestinal barrier biology: specific strains (e.g., W23/W28) show strong epithelial adhesion and mucus-layer interactions and are reported to enhance epithelial barrier integrity in experimental systems, consistent with a role in maintaining gut homeostasis. Second, there is compelling preclinical evidence that B. bifidum can modulate immune–metabolic pathways relevant to disease phenotypes in animal models, including anti-inflammatory effects in colitis models and an antitumour effect in mice under calorie restriction that is microbiota-dependent and linked to acetate production and interferon-γ–associated immune responses. In contrast, for metabolic liver disease (NAFLD/MASLD), the abstracts emphasize gut microbiota–derived metabolites (e.g., indole derivatives) and inflammatory signaling (e.g., NF-κB) as important mechanisms, but do not establish B. bifidum as a primary causal driver in humans within the provided material.

Key gaps remain. Much of the mechanistic and efficacy evidence is preclinical (cell systems and mouse models), and translation to humans requires well-powered, strain-resolved randomized controlled trials with standardized endpoints (barrier function, inflammation, clinical outcomes) and careful control of diet and baseline microbiome composition. Additional needs include: clearer mapping from B. bifidum strain genomics to functional outputs (e.g., mucin glycan utilization, short-chain fatty acid profiles), dose–response and durability of colonization in adults (where bifidobacteria are typically lower abundance), and rigorous safety characterization (including antibiotic resistance and virulence/toxin screening) as recommended in probiotic safety frameworks. Finally, emerging areas—such as microbiome–immune crosstalk in early life and microbiome influences on cancer therapy response—would benefit from studies that explicitly test B. bifidum’s causal role, mechanisms, and interaction with other community members across developmental stages.

1. What conditions has B. bifidum been studied for?

  • Gut barrier dysfunction / epithelial integrity (mechanistic cell/epithelial models): specific B. bifidum strains (W23, W28, type strain 20456) were screened for effects on mucin biology (MUC13) and barrier function.

  • Ulcerative colitis / colitis (animal models): B. bifidum ATCC 29521 studied in DSS-induced colitis in mice; additional UC-related work mentioned using B. bifidum WBIN03 (and in combination with Lactobacillus plantarum).

  • Constipation (animal model): compared across multiple edible Bifidobacterium species in loperamide-induced constipation in mice; B. bifidum was among the most effective species.

  • Cancer / antitumour immunity (mouse tumour model): in calorie restriction (CR) experiments, B. bifidum administration rescued CR’s antitumour effect in microbiota-depleted mice (MC38 subcutaneous tumour model).

  • Parkinson’s disease medication interaction (clinical association + in vitro): commensal Bifidobacterium (including B. bifidum) studied for metabolism of levodopa (L-DOPA) to DHPLA.

  • Metabolic liver disease (NAFLD/MASLD): the provided MASLD abstract focuses on indole metabolites (IPA/IAA) improving steatosis in animals; it does not directly test B. bifidum, but it frames gut microbiota metabolites as mechanistically relevant to fatty liver disease.

  • Bone health / osteoporosis: an osteoporosis/probiotics abstract is included but is truncated; it indicates probiotic strains (including bifidobacteria) are being studied for bone density/bone loss, without clear B. bifidum-specific outcomes in the excerpt.

  • Early-life microbiome development / immune crosstalk: background-level evidence that early microbiome development influences immune programming and later disease risk; B. bifidum is described as common/dominant in infants in review-style excerpts.

  • Drug-induced liver injury / drug metabolism modulation: a voriconazole hepatotoxicity abstract mentions gut microbiota changes with an intervention (APS) that increases abundance of some taxa; the excerpt is incomplete and does not clearly identify B. bifidum as the key organism, but it is within the theme of microbiome-mediated drug metabolism/toxicity.

2. Does it work in treating those conditions? Summarize the evidence.

  • Gut barrier integrity: supportive mechanistic evidence (strain-specific). In a screening study, B. bifidum strains W23 and W28 (and type strain 20456) were characterized; W23/W28 adhered strongly to the apical surface, had high sialidase activity, penetrated mucus, and enhanced epithelial barrier integrity. This supports plausibility for barrier-related benefits, but it is not a clinical outcomes trial.

  • Colitis/UC: supportive preclinical evidence. A DSS-induced colitis mouse study investigated B. bifidum ATCC 29521 and describes “beneficial role and mechanisms” (including miRNA-related mechanisms), implying improvement versus DSS alone; however, the excerpt is truncated, so effect sizes and endpoints cannot be verified here. Another UC-oriented abstract mentions B. bifidum WBIN03 (alone/combined) for anti-inflammatory/antioxidant effects, but details are not provided in the excerpt.

  • Constipation: supportive preclinical evidence with interspecies comparison. In loperamide-induced constipation in mice, B. bifidum was among the most effective species (along with B. longum and B. infantis) for improving constipation indicators. The study also linked benefit to higher fecal short-chain fatty acids (SCFAs), especially acetate, and shifts in fecal flora (e.g., increased Lactobacillus).

  • Cancer (tumour growth in mice): supportive causal evidence in a specific model. In female mice, calorie restriction (CR) protected against MC38 tumour formation in a gut-microbiota-dependent manner. After CR, Bifidobacterium was enriched, and B. bifidum administration was sufficient to rescue the antitumour effect of CR in microbiota-depleted mice. Mechanistically, the effect depended on acetate production and interferon-γ accumulation. This is strong preclinical causality for that model, but not proof of benefit in humans or outside CR context.

  • Parkinson’s disease (L-DOPA): evidence suggests a potential negative interaction rather than “treatment.” In PD patients, Bifidobacterium abundance correlated positively with L-DOPA dose and negatively with serum tyrosine. In vitro, several species including B. bifidum metabolized L-DOPA to DHPLA (upregulated in nutrient-limited conditions). This suggests B. bifidum could contribute to peripheral drug metabolism under some conditions, but the clinical impact on L-DOPA efficacy is not established in the excerpt.

  • MASLD/NAFLD and osteoporosis: insufficient B. bifidum-specific efficacy evidence in the provided excerpts. The MASLD abstract demonstrates benefit of indole metabolites (IPA/IAA) in animals, but does not test B. bifidum. The osteoporosis excerpt is incomplete and does not allow conclusions about B. bifidum efficacy.

3. What health benefits does it have?

  • Supports intestinal barrier function (strain-specific). B. bifidum W23/W28 enhanced epithelial barrier integrity and showed mucus-layer penetration and strong epithelial adherence; the study also highlights interaction with mucin biology (MUC13 O-glycan degradation), suggesting a mechanism for barrier modulation.

  • May reduce intestinal inflammation in preclinical colitis models. DSS-colitis work with B. bifidum ATCC 29521 (and other UC-related abstracts) indicates anti-inflammatory mechanisms are being studied, including miRNA regulation (details not fully available in the excerpt).

  • May improve constipation in animal models. In mice, B. bifidum improved constipation outcomes and was associated with increased SCFAs (notably acetate) and favorable microbiota shifts (e.g., increased Lactobacillus and reduced potentially unfavorable genera such as Alistipes, Odoribacter, Clostridium).

  • Potential antitumour immune support in a specific mouse context. In CR-associated tumour protection, B. bifidum mediated an acetate- and interferon-γ-dependent antitumour effect in mice.

  • Life-course presence and potential role in healthy microbiome ecology. A large Japanese cohort (0–104 years) found B. bifidum detectable at almost all ages, supporting that it is a common commensal across the lifespan. Review excerpts also emphasize bifidobacteria as prominent in breast-fed infants and associated with production of potentially beneficial metabolites (e.g., SCFAs; reviews also mention conjugated linoleic acid and bacteriocins at the genus level).

4. Does it have any downsides or side effects?

  • Potential drug–microbe interaction with L-DOPA (possible downside in PD). In vitro, B. bifidum can metabolize L-DOPA to DHPLA, and in PD cohorts higher Bifidobacterium abundance correlated with higher L-DOPA dose. The excerpt does not prove worsened clinical response, but it raises a plausible risk that some commensal bifidobacteria could contribute to peripheral L-DOPA metabolism under certain conditions.

  • Mucin degradation is double-edged and likely strain/context dependent. The barrier study reports a B. bifidum strain uniquely degraded the MUC13 O-glycosylated extracellular domain and that W23/W28 penetrated mucus while enhancing barrier integrity. While the net effect reported was beneficial for barrier integrity, mucin-degrading capacity could theoretically be harmful in some contexts (e.g., if it thins protective mucus), but the provided excerpt does not show harm outcomes.

  • General probiotic safety considerations (not B. bifidum-specific in the excerpts). One abstract notes that some lactic acid bacteria can produce toxic substances or show virulence traits and references FAO/WHO guidance for safety characterization (e.g., antibiotic resistance, toxin production, hemolysis, infectivity in immunocompromised animals, human adverse outcomes). The excerpt does not report specific adverse events for B. bifidum, but it underscores the need for strain-level safety evaluation.

  • Human side-effect data are not provided in these excerpts. None of the included abstracts (as provided) report rates of gastrointestinal side effects, infections, or other adverse events in humans specifically attributable to B. bifidum.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report clear host genetic variants that predict benefit or harm from B. bifidum supplementation (i.e., no explicit pharmacogenomic markers).

  • Drug metabolism interaction is microbiome-driven rather than host-genotype-driven in the excerpts. The Parkinson’s/L-DOPA abstract describes microbial metabolism of L-DOPA by B. bifidum (and other bifidobacteria) via existing tyrosine-metabolizing genes in the bacteria; it does not link effects to human genetic polymorphisms (e.g., in COMT, DDC, MAO, transporters).

  • Implication (limited): If future studies show that microbial L-DOPA metabolism meaningfully alters drug exposure, then host genotypes affecting L-DOPA pharmacokinetics/pharmacodynamics could interact with microbiome composition, but that interaction is not demonstrated in the provided text.

References

  1. Temporal development of the gut microbiome in early childhood from the TEDDY study.
    Christopher J Stewart, Nadim J Ajami, Jacqueline L O'Brien, Diane S Hutchinson, Daniel P Smith, Matthew C Wong, Matthew C Ross, Richard E Lloyd, HarshaVardhan Doddapaneni, Ginger A Metcalf, Donna Muzny, Richard A Gibbs, Tommi Vatanen, Curtis Huttenhower, Ramnik J Xavier, Marian Rewers, William Hagopian, Jorma Toppari, Anette-G Ziegler, Jin-Xiong She, Beena Akolkar, Ake Lernmark, Heikki Hyoty, Kendra Vehik, Jeffrey P Krischer, Joseph F Petrosino (2018) - Nature
  2. Gut Bifidobacteria Populations in Human Health and Aging.
    Silvia Arboleya, Claire Watkins, Catherine Stanton, R Paul Ross (2016) - Frontiers in microbiology
  3. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.
    Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak Han, Dong Joon Kim, Ki Tae Suk (2024) - Gut microbes
  4. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice.
    Se-Hoon Lee, Sung-Yup Cho, Youngmin Yoon, Changho Park, Jinyoung Sohn, Jin-Ju Jeong, Bu-Nam Jeon, Mongjoo Jang, Choa An, Suro Lee, Yun Yeon Kim, Gihyeon Kim, Sujeong Kim, Yunjae Kim, Gwang Bin Lee, Eun Ju Lee, Sang Gyun Kim, Hong Sook Kim, Yeongmin Kim, Hyun Kim, Hyun-Suk Yang, Sarang Kim, Seonggon Kim, Hayung Chung, Myeong Hee Moon, Myung Hee Nam, Jee Young Kwon, Sungho Won, Joon-Suk Park, George M Weinstock, Charles Lee, Kyoung Wan Yoon, Hansoo Park (2021) - Nature microbiology
  5. Recent Development of ProbioticBifidobacteriafor Treating Human Diseases
    Jun Chen, Xinyi Chen, Chun Loong Ho (2021)
  6. Bifidobacterium improves oestrogen-deficiency-induced osteoporosis in mice by modulating intestinal immunity.
    Jincan Zhang, Xi Liang, Xiaoying Tian, Maozhen Zhao, Yunjuan Mu, Huaxi Yi, Zhe Zhang, Lanwei Zhang (2024) - Food & function
  7. Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of
    Jing Lu, Dilireba Shataer, Huizhen Yan, Xiaoxiao Dong, Minwei Zhang, Yanan Qin, Jie Cui, Liang Wang (2024) - Foods (Basel, Switzerland)
  8. Probiotic Bifidobacterium bifidum strains desialylate MUC13 and increase intestinal epithelial barrier function.
    Celia Segui-Perez, Liane Z X Huang, Fernanda L Paganelli, Elke Lievens, Karin Strijbis (2025) - Scientific reports
  9. The antitumour effects of caloric restriction are mediated by the gut microbiome.
    Yu-Qin Mao, Jia-Ting Huang, Shi-Long Zhang, Chao Kong, Zhan-Ming Li, Hui Jing, Hui-Ling Chen, Chao-Yue Kong, Sheng-Hui Huang, Pei-Ran Cai, Bing Han, Li-Shun Wang (2023) - Nature metabolism
  10. Age-Related Changes in the Composition of Gut Bifidobacterium Species.
    Kumiko Kato, Toshitaka Odamaki, Eri Mitsuyama, Hirosuke Sugahara, Jin-Zhong Xiao, Ro Osawa (2017) - Current microbiology
  11. Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism.
    Ahmad Ud Din, Adil Hassan, Yuan Zhu, Kun Zhang, Yi Wang, Tianhan Li, Yang Wang, Guixue Wang (2020) - The Journal of nutritional biochemistry
  12. Safety Evaluations of
    Min Jeong Kim, Seockmo Ku, Sun Young Kim, Hyun Ha Lee, Hui Jin, Sini Kang, Rui Li, Tony V Johnston, Myeong Soo Park, Geun Eog Ji (2018) - International journal of molecular sciences
  13. Hawthorn pectin mitigates high-fat diet induced hyperlipidemia in mice through promoting Dubosiella newyorkensis.
    Qianyun Zhao, Yubin Liu, Mingxing Li, Long Zhao, Tiangang Wang, Yaqin Xiao, Shulin Wei, Ke Wu, Jiayue Yang, Yaqiu Wang, Yueshui Zhao, Fukuan Du, Yu Chen, Shuai Deng, Jing Shen, Zhangang Xiao, Zhi Li, Shengpeng Wang, Xu Wu (2025) - Carbohydrate polymers
  14. Bifidobacterium bifidum: A Key Member of the Early Human Gut Microbiota.
    Francesca Turroni, Sabrina Duranti, Christian Milani, Gabriele Andrea Lugli, Douwe van Sinderen, Marco Ventura (2019) - Microorganisms
  15. Administration of
    Hongwon Kim, Sumin Kim, Sang-Jun Park, Gwoncheol Park, Hakdong Shin, Myeong Soo Park, Jongpil Kim (2021) - Frontiers in aging neuroscience
  16. Bifidobacterium bifidum Ameliorates DSS-Induced Colitis in Mice by Regulating Microbial Metabolome and Targeting Gut Microbiota.
    Mengzhen Han, Jingjing Liang, Mengxin Hou, Yuanye Liu, Hongcai Li, Zhenpeng Gao (2024) - Journal of agricultural and food chemistry
  17. Bifidobacteria exert species-specific effects on constipation in BALB/c mice.
    Linlin Wang, Lujun Hu, Qi Xu, Tian Jiang, Shuguang Fang, Gang Wang, Jianxin Zhao, Hao Zhang, Wei Chen (2017) - Food & function
  18. A novel pathway of levodopa metabolism by commensal Bifidobacteria.
    M S Cirstea, A Creus-Cuadros, C Lo, A C Yu, A Serapio-Palacios, S Neilson, S Appel-Cresswell, B B Finlay (2023) - Scientific reports
  19. Potential of Lactobacillus plantarum ZDY2013 and Bifidobacterium bifidum WBIN03 in relieving colitis by gut microbiota, immune, and anti-oxidative stress.
    Yuanyuan Wang, Yilin Guo, Hui Chen, Hua Wei, Cuixiang Wan (2018) - Canadian journal of microbiology
  20. Astragalus Polysaccharide Enhances Voriconazole Metabolism under Inflammatory Conditions through the Gut Microbiota.
    Xiaokang Wang, Xianjing Hu, Chunxiao Ye, Jingqian Zhao, Shing Cheng Tan, Liangbin Zhou, Chenyu Zhao, Kit Hang Wu, Xixiao Yang, Jinbin Wei, Maoxun Yang (2024) - Journal of clinical and translational hepatology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!